[
    [
        {
            "time": "2018-01-02",
            "original_text": "Daily Dividend Report: VICI, WPC, ABBV, BMY, EQR",
            "features": {
                "keywords": [
                    "VICI",
                    "WPC",
                    "ABBV",
                    "BMY",
                    "EQR"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "real estate",
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Daily Dividend Report: VICI, WPC, ABBV, BMY, EQR",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-03",
            "original_text": "MARKETS: Here's why stocks are dropping right now",
            "features": {
                "keywords": [
                    "stocks",
                    "dropping"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "MARKETS: Here's why stocks are dropping right now",
                "Correlation": 4,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc",
            "features": {
                "keywords": [
                    "AbbVie",
                    "GlaxoSmithKline"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "3 High-Yield Stocks at Rock-Bottom Prices",
            "features": {
                "keywords": [
                    "High-Yield",
                    "Stocks",
                    "Rock-Bottom"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "3 High-Yield Stocks at Rock-Bottom Prices",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 4,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals",
            "features": {
                "keywords": [
                    "LLY",
                    "AZN",
                    "Alzheimer's",
                    "MRK",
                    "Keytruda"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-07",
            "original_text": "Analysis: Positioning to Benefit within Canopy Growth, Aurora Cannabis, CannTrust, AbbVie, Cronos Group, and Scotts Miracle-Gro — Research Highlights Growth, Revenue, and Consolidated Results",
            "features": {
                "keywords": [
                    "Canopy Growth",
                    "Aurora Cannabis",
                    "CannTrust",
                    "AbbVie",
                    "Cronos Group",
                    "Scotts Miracle-Gro"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "cannabis",
                    "healthcare",
                    "consumer goods"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Analysis: Positioning to Benefit within Canopy Growth, Aurora Cannabis, CannTrust, AbbVie, Cronos Group, and Scotts Miracle-Gro — Research Highlights Growth, Revenue, and Consolidated Results",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-08",
            "original_text": "AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Venetoclax",
                    "Rituximab",
                    "MURANO Trial",
                    "Chronic Lymphocytic Leukemia"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 10,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]